Test-retest reliability of [11C]AZ10419369 binding to 5-HT 1B receptors in human brain

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 41, Issue 2, 2014, Pages 301-307

  Nord, Magdalena ^a   Finnema, Sjoerd J ^a   Schain, Martin ^a   Halldin, Christer ^a   Farde, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Brain Imaging; PET; Test retest

Indexed keywords

AZ 10419369 C 11; RADIOLIGAND; SEROTONIN 1B RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CEREBELLUM; CEREBELLUM CORTEX; CORRELATION COEFFICIENT; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; MALE; NEUROIMAGING; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SCANNER; OCCIPITAL CORTEX; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RAPHE NUCLEUS; TEMPORAL CORTEX; TEST RETEST RELIABILITY; THALAMUS; YOUNG ADULT;

ADULT; BENZOPYRANS; DATA INTERPRETATION, STATISTICAL; HUMANS; MALE; MORPHOLINES; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RAPHE NUCLEI; RECEPTOR, SEROTONIN, 5-HT1B; REPRODUCIBILITY OF RESULTS;

EID: 84897880775     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-013-2529-1     Document Type: Article

References (28)

1. Sari Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004;28:565-82.
2. Ruf BM, Bhagwagar Z. The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets. 2009;10:1118-38.
3. Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy Eur J Neurol. 2002;9 Suppl 3:1-6.
4. Varnas K, Jucaite A, McCarthy DJ, Stenkrona P, Nord M, Halldin C, et al. A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers. Cephalalgia. 2013;33:853-60.
5. Varnas K, Hall H, Bonaventure P, Sedvall G. Autoradiographic mapping of 5-HT(1B) and 5-HT(1D) receptors in the post mortem human brain using [3H]GR 125743. Brain Res. 2001;915:47-57.
6. Varnas K, Hurd YL, Hall H. Regional expression of 5-HT1B receptor mRNA in the human brain. Synapse. 2005;56:21-8.
7. Adell A, Celada P, Artigas F. The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem. 2001;79:172-82.
8. Varnas K, Nyberg S, Halldin C, Varrone A, Takano A, Karlsson P, et al. Quantitative analysis of [11C]AZ 10419369 binding to 5-HT1B receptors in human brain. J Cereb Blood Flow Metab. 2011;31:113-23.
9. Pierson ME, Andersson J, Nyberg S, McCarthy DJ, Finnema SJ, Varnas K, et al. [11C]AZ10419369: a selective 5-HT1B receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. Neuroimage. 2008;41:1075-85.
10. Andersson JD, Pierson ME, Finnema SJ, Gulyas B, Heys R, Elmore CS, et al. Development of a PET radioligand for the central 5-HT1B receptor: radiosynthesis and characterization in cynomolgus monkeys of eight radiolabeled compounds. Nucl Med Biol. 2011;38:261-72.
11. Finnema SJ, Varrone A, Hwang TJ, Gulyas B, Pierson ME, Halldin C, et al. Fenfluramine-induced serotonin release decreases [11C]AZ10419369 binding to 5-HT(1B)-receptors in the primate brain. Synapse. 2010;64:573-7.
12. Nord M, Finnema SJ, Halldin C, Farde L. Effect of a single dose of escitalopram on serotonin concentration in the non-human and human primate brain. Int J Neuropsychopharmacol. 2013;16:1577-86.
13. Finnema SJ, Varrone A, Hwang TJ, Halldin C, Farde L. Confirmation of fenfluramine effect on 5-HT(1B) receptor binding of [11C]AZ10419369 using an equilibrium approach. J Cereb Blood Flow Metab. 2012;32:685-95.
14. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;20(59 Suppl):22-33; quiz 4-57.
15. Derry C, Benjamin C, Bladin P, le Bars D, Tochon-Danguy H, Berkovic SF, et al. Increased serotonin receptor availability in human sleep: evidence from an [18F]MPPF PET study in narcolepsy. Neuroimage. 2006;30:341-8.
16. Varrone A, Sjoholm N, Eriksson L, Gulyas B, Halldin C, Farde L. Advancement in PET quantification using 3D-OP-OSEM point spread function reconstruction with the HRRT. Eur J Nucl Med Mol Imaging. 2009;36:1639-50.
17. Schain M, Toth M, Cselenyi Z, Stenkrona P, Halldin C, Farde L, et al. Quantification of serotonin transporter availability with [11C] MADAM - a comparison between the ECAT HRRT and HR systems. Neuroimage. 2012;60:800-7.
18. Bonaventure P, Schotte A, Cras P, Leysen JE. Autoradiographic mapping of 5-HT1B- and 5-HT1D receptors in human brain using [3H]alniditan, a new radioligand. Receptors Channels. 1997;5:225-30.
19. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-9.
20. Cselenyi Z, Olsson H, Farde L, Gulyas B. Wavelet-aided parametric mapping of cerebral dopamine D2 receptors using the high affinity PET radioligand [11C]FLB 457. Neuroimage. 2002;17:47-60.
21. McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1:30-46.
22. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86:420-8.
23. Alakurtti K, Aalto S, Johansson JJ, Nagren K, Tuokkola T, Oikonen V, et al. Reproducibility of striatal and thalamic dopamine D2 receptor binding using [11C]raclopride with high-resolution positron emission tomography. J Cereb Blood Flow Metab. 2011;31:155-65.
24. Lundberg J, Halldin C, Farde L. Measurement of serotonin transporter binding with PET and [11C]MADAM: a test-retest reproducibility study. Synapse. 2006;60:256-63.
25. Hirvonen J, Kajander J, Allonen T, Oikonen V, Nagren K, Hietala J. Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635 - considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab. 2007;27:185-95.
26. Jovanovic H, Cerin A, Karlsson P, Lundberg J, Halldin C, Nordstrom AL. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res. 2006;148:185-93.
27. Paterson LM, Kornum BR, Nutt DJ, Pike VW, Knudsen GM. 5-HT radioligands for human brain imaging with PET and SPECT. Med Res Rev. 2013;33:54-111.
28. Selvaraj S, Turkheimer F, Rosso L, Faulkner P, Mouchlianitis E, Roiser JP, et al. Measuring endogenous changes in serotonergic neurotransmission in humans: a [11C]CUMI-101 PET challenge study. Mol Psychiatry. 2012;17:1254-60.